product name BAPTA-AM
Description: BAPTA-AM is a selective, membrane-permeable calcium chelator. In the human leukemia cell lines HL-60 and U937, BAPTA/AM (10 μM) induced internucleosomal DNA cleavage and classic apoptotic morphology. Also, BAPTA/AM increased Ca2+ in intracellular and downregulated c-jun. In bovine chromaffin cells, APTA-AM (50 μM) rapidly and reversibly inhibited Ca2+-activated K+ (I(KCa)) and voltage-gated K+ (I(K)) by 50%. In HEK 293 cells, BAPTA-AM inhibited hERG (Kv11.1), hKv1.3 and hKv1.5 channels with IC50 values of 1.3, 1.45 and 1.23 μM respectively in a concentration dependent way.
References: Prog Neuropsychopharmacol Biol Psychiatry. 2001 Nov;25(8):1641-59; Biochem Pharmacol.
764.68
Formula
C34H40N2O18
CAS No.
126150-97-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 20 mg/mL (26.2 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: BAPTA-AM, as an intracellular calcium chelator, induces delayed necrosis by lipoxygenase-mediated free radicals in mouse cortical cultures. BAPTA-AM exerts an open channel blocking effect on hERG, hKv1.3 and hKv1.5 channels with IC50 of 1.3, 1.45 and 1.23 μM in HEK 293 cells. Kinase Assay: Cell Assay: In the human leukemia cell lines HL-60 and U937, BAPTA/AM (10 μM) induced internucleosomal DNA cleavage and classic apoptotic morphology. Also, BAPTA/AM increased Ca2+ in intracellular and downregulated c-jun. In bovine chromaffin cells, APTA-AM (50 μM) rapidly and reversibly inhibited Ca2+-activated K+ (I(KCa)) and voltage-gated K+ (I(K)) by 50%. In HEK 293 cells, BAPTA-AM inhibited hERG (Kv11.1), hKv1.3 and hKv1.5 channels with IC50 values of 1.3, 1.45 and 1.23 μM respectively in a concentration dependent way, which was dependent on channel opening. |
|---|---|
| In Vivo | BAPTA-AM abolishes the UDCA- and TUDCA-induced increases in Ca2+ levels or Ca2+-Dependent PKC-α phosphorylation, and neutralizes the cytoprotective effects of UDCA and TUDCA on the vagotomy-induced damage of the biliary tree in the BDL rats. |
| Animal model | BDL rats |
| Formulation & Dosage | Dissolved in 0.1% DMSO; 6 mg/kg; i.p. injection |
| References | Prog Neuropsychopharmacol Biol Psychiatry. 2001 Nov;25(8):1641-59; Biochem Pharmacol. 2007 Dec 3;74(11):1596-607; Am J Pathol. 2006 Feb;168(2):398-409. |
